Security key
171126204
Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS)
CUSIP: 171126204
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 3,332,442
- Total 13F shares
- 899,359
- Share change
- +436,597
- Total reported value
- $27,880,129
- Price per share
- $31.00
- Number of holders
- 15
- Value change
- +$13,536,994
- Number of buys
- 14
- Number of sells
- 3
Report period
Q4 2025
Institutions
15
Top holders
10
PTHS full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Pelthos Therapeutics Inc. SEC filings
Pelthos Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 171126204
Recent filing periods:
Top shareholders of PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC |
13D/G
3/4/5
|
Ligand Pharmaceuticals Incorporated · Director, 10%+ Owner |
50%
|
5,189,177
|
$145,296,959 | +$7,316,652 | 06 Nov 2025 | |
| Alexandra Wood (Canada) Inc. |
13D/G
|
— |
9.5%
|
574,187
|
$734,959 | $0 | 13 Dec 2024 | |
| Murchinson Ltd. |
13D/G
13F
|
Company |
9.1%
|
280,000
|
$7,840,000 | $0 | 30 Sep 2025 | |
| Ezra M. Friedberg |
13D/G
|
Ezra Friedberg |
8.3%
|
250,121
|
— | $0 | 01 Jul 2025 | |
| Ikarian Capital, LLC |
13F
13D/G
|
Company |
7.3%
from 13D/G
|
62,451
|
$1,748,628 | — | 30 Sep 2025 | |
| Andrew J. Einhorn |
3/4/5
|
Director |
0.36%
|
12,000
|
$342,000 | — | 23 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
66,836
|
$1,871,408 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.64%
|
21,245
|
$594,860 | — | 30 Sep 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.32%
|
10,498
|
$293,944 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.31%
|
10,330
|
$289,240 | — | 30 Sep 2025 | |
| David M. Knott Jr. |
13F
|
Individual |
0.18%
|
6,112
|
$171,136 | — | 30 Sep 2025 | |
| Persistent Asset Partners Ltd |
13F
|
Company |
0.07%
|
2,403
|
$67,284 | — | 30 Sep 2025 | |
| Steward Partners Investment Advisory, LLC |
13F
|
Company |
0.06%
|
1,910
|
$53,480 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
827
|
$23,156 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
137
|
$3,836 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
11
|
$308 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
1
|
$28 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1
|
$28 | — | 30 Sep 2025 | |
| Motif Pharmaceuticals Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
470,674
|
$442,434 | — | 15 Feb 2024 | |
| Boswell Prayer Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
459,895
|
$432,301 | — | 15 Feb 2024 | |
| Aperture Healthcare Ventures Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
426,566
|
$400,972 | — | 15 Feb 2024 | |
| AME Equities LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
351,163
|
$330,093 | — | 15 Feb 2024 | |
| Todd C. Davis |
3/4/5
|
Director |
—
mixed-class rows
|
4,762,953
mixed-class rows
|
$16,264,921 | — | 02 Jul 2025 | |
| Scott M. Plesha |
3/4/5
|
CEO and President, Director |
—
mixed-class rows
|
422,356
mixed-class rows
|
$2,117,890 | — | 02 Jul 2025 | |
| Sai Rangarao |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
154,036
mixed-class rows
|
$772,410 | — | 02 Jul 2025 | |
| Richard B. Baxter |
3/4/5
|
Director |
—
mixed-class rows
|
96,446
mixed-class rows
|
$483,623 | — | 02 Jul 2025 | |
| Chia-Lin Simmons |
3/4/5
|
Director |
—
class O/S missing
|
235,000
|
— | — | 11 Apr 2025 | |
| Eric Lang |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
154,223
|
— | — | 14 Jun 2024 |
Institutional Holders of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) as of Q4 2025
As of 31 Dec 2025,
Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
899,359 shares.
The largest 10 holders included
Murchinson Ltd., Ikarian Capital, LLC, BOOTHBAY FUND MANAGEMENT, LLC, J. Goldman & Co LP, VANGUARD GROUP INC, CANTOR FITZGERALD, L. P., DIADEMA PARTNERS LP, Knott David M Jr, GEODE CAPITAL MANAGEMENT, LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
15
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
14
Q4 2025 holders
15
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.